MedTrace Logo

Sports Nutrition Benefits of Weizmannia Coagulans BC99

NCT07325409 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-01-08

No results posted yet for this study

Summary

To evaluate the clinical efficacy of Weizmannia coagulans BC99 in young Chinese patients with exercise-induced muscle damage compared with placebo, and to explore its effects on inflammatory responses and intestinal microbiota.

Conditions

  • College Students of the School of Physical Education

Interventions

DIETARY_SUPPLEMENT

Placebo

The experimental phase of this study lasts 12 weeks and each participant will have 3 visits (week 0, week 6, week 12)

DIETARY_SUPPLEMENT

BC99

The experimental phase of this study lasts 12 weeks and each participant will have 3 visits (week 0, week 6, week 12)

Sponsors & Collaborators

  • Wecare Probiotics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2024-03-10
Completion
2024-03-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07325409 on ClinicalTrials.gov